Robbins LLP Informs Investors of Gossamer Bio Class Action Lawsuit

Lawsuit alleges biotech company misled investors about drug development progress.

Apr. 1, 2026 at 7:43pm

Got story updates? Submit your updates here. ›

The law firm Robbins LLP has filed a class action lawsuit against Gossamer Bio, Inc., a San Diego-based biopharmaceutical company, on behalf of investors. The lawsuit alleges that Gossamer Bio made false and misleading statements about the progress and likelihood of success for one of its key drug candidates, leading to significant losses for shareholders when the truth was revealed.

Why it matters

Investor lawsuits against biotech companies are relatively common, as these firms often make bold claims about their drug pipelines that don't always pan out. This case highlights the risks faced by investors in the volatile biotech sector, where even small missteps or misrepresentations can lead to major stock price swings and legal battles.

The details

According to the lawsuit, Gossamer Bio repeatedly touted the progress and prospects of its GB001 drug, which was being developed to treat respiratory diseases. However, the lawsuit alleges the company knew or should have known that GB001 was unlikely to succeed in clinical trials, but failed to disclose this information to investors. When Gossamer Bio eventually announced that GB001 had failed in a key study, the company's stock price plummeted, causing significant losses for shareholders.

  • The class action lawsuit was filed on April 1, 2026.

The players

Robbins LLP

A law firm that specializes in shareholder rights litigation and has filed the class action lawsuit against Gossamer Bio on behalf of investors.

Gossamer Bio, Inc.

A San Diego-based biopharmaceutical company that is the defendant in the class action lawsuit, accused of making false and misleading statements about the progress of one of its drug candidates.

Got photos? Submit your photos here. ›

What they’re saying

“We must hold Gossamer Bio accountable for the harm it has caused investors through its deceptive practices.”

— Brian Robbins, Founding Partner, Robbins LLP

What’s next

The lawsuit is in the early stages, and a judge will need to decide whether to certify the case as a class action. If certified, the case will then proceed to the discovery phase.

The takeaway

This case underscores the importance of biotech companies providing accurate and transparent information to investors, who rely on such disclosures to make informed decisions. The lawsuit against Gossamer Bio serves as a warning to other firms in the sector to be diligent in their reporting.